86 related articles for article (PubMed ID: 7518523)
1. Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors.
Dow RL; Chou TT; Bechle BM; Goddard C; Larson ER
J Med Chem; 1994 Jul; 37(14):2224-31. PubMed ID: 7518523
[TBL] [Abstract][Full Text] [Related]
2. Nonphosphorylatable tyrosine surrogates. Implications for protein kinase inhibitor design.
Niu J; Lawrence DS
J Biol Chem; 1997 Jan; 272(3):1493-9. PubMed ID: 8999819
[TBL] [Abstract][Full Text] [Related]
3. DNA gyrase inhibitory activity of ellagic acid derivatives.
Weinder-Wells MA; Altom J; Fernandez J; Fraga-Spano SA; Hilliard J; Ohemeng K; Barrett JF
Bioorg Med Chem Lett; 1998 Jan; 8(1):97-100. PubMed ID: 9871636
[TBL] [Abstract][Full Text] [Related]
4. New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C.
Kashiwada Y; Huang L; Ballas LM; Jiang JB; Janzen WP; Lee KH
J Med Chem; 1994 Jan; 37(1):195-200. PubMed ID: 8289196
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and anti-tyrosine kinase activity of 3-(substituted-benzylidene)-1, 3-dihydro-indolin derivatives: investigation of their role against p60c-Src receptor tyrosine kinase with the application of receptor docking studies.
Olgen S; Akaho E; Nebioglu D
Farmaco; 2005; 60(6-7):497-506. PubMed ID: 15927182
[TBL] [Abstract][Full Text] [Related]
6. Amiloride inhibits the protein tyrosine kinases associated with the cellular and the transforming src-gene products.
Presek P; Reuter C
Biochem Pharmacol; 1987 Sep; 36(17):2821-6. PubMed ID: 2443144
[TBL] [Abstract][Full Text] [Related]
7. Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.
Cozza G; Bonvini P; Zorzi E; Poletto G; Pagano MA; Sarno S; Donella-Deana A; Zagotto G; Rosolen A; Pinna LA; Meggio F; Moro S
J Med Chem; 2006 Apr; 49(8):2363-6. PubMed ID: 16610779
[TBL] [Abstract][Full Text] [Related]
8. A tyrphostin-derived inhibitor of protein tyrosine kinases: isolation and characterization.
Ramdas L; Obeyesekere NU; McMurray JS; Gallick GE; Seifert WE; Budde RJ
Arch Biochem Biophys; 1995 Nov; 323(2):237-42. PubMed ID: 7487083
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60(c-src).
Thompson AM; Rewcastle GW; Boushelle SL; Hartl BG; Kraker AJ; Lu GH; Batley BL; Panek RL; Showalter HD; Denny WA
J Med Chem; 2000 Aug; 43(16):3134-47. PubMed ID: 10956222
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
11. Effects of protein tyrosine kinase inhibitors on voltage-operated calcium channel currents in vascular smooth muscle cells and pp60(c-src) kinase activity.
Wijetunge S; Lymn JS; Hughes AD
Br J Pharmacol; 2000 Apr; 129(7):1347-54. PubMed ID: 10742290
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of indole esters as inhibitors of p60(c-Src) receptor tyrosine kinase and investigation of the inhibition using receptor docking studies.
Olgen S; Akaho E; Nebioglu D
J Enzyme Inhib Med Chem; 2003 Dec; 18(6):485-90. PubMed ID: 15008512
[TBL] [Abstract][Full Text] [Related]
13. Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines.
Tian G; Cory M; Smith AA; Knight WB
Biochemistry; 2001 Jun; 40(24):7084-91. PubMed ID: 11401553
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of eukaryote serine/threonine-specific protein kinases by piceatannol.
Wang BH; Lu ZX; Polya GM
Planta Med; 1998 Apr; 64(3):195-9. PubMed ID: 9581512
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
16. Cyclic peptides incorporating 4-carboxyphenylalanine and phosphotyrosine are potent inhibitors of pp60(c-)(src).
Wang W; Ramdas L; Sun G; Ke S; Obeyesekere NU; Budde RJ; McMurray JS
Biochemistry; 2000 May; 39(17):5221-8. PubMed ID: 10819990
[TBL] [Abstract][Full Text] [Related]
17. Natural flavonoids as antidiabetic agents. The binding of gallic and ellagic acids to glycogen phosphorylase b.
Kyriakis E; Stravodimos GA; Kantsadi AL; Chatzileontiadou DS; Skamnaki VT; Leonidas DD
FEBS Lett; 2015 Jul; 589(15):1787-94. PubMed ID: 25980608
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
19. Involvement of phosphoinositide 3-kinase and its association with pp60src in cholecystokinin-stimulated pancreatic acinar cells.
Nozu F; Owyang C; Tsunoda Y
Eur J Cell Biol; 2000 Nov; 79(11):803-9. PubMed ID: 11139143
[TBL] [Abstract][Full Text] [Related]
20. Kinetic mechanisms of the forward and reverse pp60c-src tyrosine kinase reactions.
Boerner RJ; Barker SC; Knight WB
Biochemistry; 1995 Dec; 34(50):16419-23. PubMed ID: 8845369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
